At the Thirteenth International Kidney Cancer Symposium, Dr James Hsieh (Memorial Sloan-Kettering Cancer Center, NY) discusses the need for clinical trials in non-clear cell renal cell carcinoma (RCC) and new research in papillary RCC (pRCC). Emerging trials in the non-clear cell RCC subtype, pRCC, are hoped to improve the availability of therapies specifically approved for this disease.